Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.425
-0.025 (-1.72%)
At close: Jun 30, 2026, 4:00 PM EDT
1.400
-0.025 (-1.75%)
After-hours: Jun 30, 2026, 4:02 PM EDT
Coherus Oncology Revenue
Coherus Oncology had revenue of $12.31M in the quarter ending March 31, 2026, with 61.99% growth. This brings the company's revenue in the last twelve months to $21.83M, up 33.50% year-over-year. In the year 2025, Coherus Oncology had annual revenue of $42.17M with 59.81% growth.
Revenue (ttm)
$21.83M
Revenue Growth
+33.50%
P/S Ratio
4.74
Revenue / Employee
$323,331
Employees
145
Market Cap
219.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.17M | 15.78M | 59.81% |
| Dec 31, 2024 | 26.39M | -230.86M | -89.74% |
| Dec 31, 2023 | 257.24M | 46.20M | 21.89% |
| Dec 31, 2022 | 211.04M | -115.51M | -35.37% |
| Dec 31, 2021 | 326.55M | -149.27M | -31.37% |
| Dec 31, 2020 | 475.82M | 119.75M | 33.63% |
| Dec 31, 2019 | 356.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 1.56M | -188.55M | -99.18% |
| Dec 31, 2016 | 190.11M | 160.07M | 532.82% |
| Dec 31, 2015 | 30.04M | -1.07M | -3.42% |
| Dec 31, 2014 | 31.11M | 28.36M | 1,030.72% |
| Dec 31, 2013 | 2.75M | 852.00K | 44.87% |
| Dec 31, 2012 | 1.90M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 151.12M |
| Codexis | 78.09M |
| Atrium Therapeutics | 36.68M |
| Voyager Therapeutics | 36.49M |
| Keros Therapeutics | 33.18M |
| Alector | 18.42M |
| Camp4 Therapeutics | 3.93M |
| Humacyte | 2.02M |
CHRS News
- 7 days ago - Coherus, Zumutor collaborate for ZM008, Loqtorzi combination study - TheFly
- 7 days ago - Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) - GlobeNewsWire
- 26 days ago - Coherus Oncology Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Coherus Oncology Proxy statement: Proxy filing - Filings
- 4 weeks ago - Coherus Oncology Transcript: AGM 2026 - Transcripts
- 7 weeks ago - Coherus Oncology reports Q1 EPS (28c), consensus (26c) - TheFly
- 7 weeks ago - Coherus Oncology Earnings Call Transcript: Q1 2026 - Transcripts
- 7 weeks ago - Coherus Oncology Earnings release: Q1 2026 - Filings